Aytu biopharma reports fiscal 2025 third quarter operational and financial results

Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectively adjusted ebitda1 of $3.9 million total net revenue of $18.5 million up 32% year-over-year company to host conference call and webcast today, may 14, 2025, at 4:30 p.m. eastern time denver, co / access newswire / may 14, 2025 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 third quarter.
AYTU Ratings Summary
AYTU Quant Ranking